Onset ── The Pleasure of Being Right

The day it began, the reviewer received a simple thank-you. A promotional brochure was hours from print when they caught an efficacy claim that edged beyond the approved label. They held their ground. The correction was made. A colleague said, in the corridor, "We'd have been in trouble without you." That was the moment rightness became a reward. The feeling was genuine. The conviction that following the rules protects patients was not wrong. But that moment was the entrance. This first episode traces the onset of what we call "justice disease" — a professional condition that is difficult to see precisely because it begins in virtue.

The Day Rightness Became a Reward

The reviewer was six years into the work. They had absorbed the spirit of the regulations, the logic of the approval framework, the rhythm of the review cycle. The routine was no longer difficult, but it had grown thin. Then came the first discovery.

The material was a patient information leaflet for a newly approved topical agent. One efficacy claim, by a narrow margin, exceeded the authorized label wording. The marketing team pushed back — "industry standard," they said. The reviewer did not move. Legal confirmed the issue the following morning. A correction order went out. A short apology arrived by email; in the hallway, a production coordinator said, "Thank you. I'm glad you caught it."

The feeling should be described carefully. It was not the retrospective satisfaction of having been proven right. It was more immediate than that. A sense of being indispensable: "If I hadn't been here, this would have gone through." A sense of direct connection: "My judgment reached the patient." Professional identity sharpened, in that moment, into something solid.

This feeling is legitimate. It is a proper form of achievement for someone in this role. The trouble is not the feeling itself. The trouble is what the mind learns when this feeling repeats.

Between a Sense of Justice and Professional Ethics

A sense of justice is necessary for this work. Inaccurate pharmaceutical information distorts the decisions of physicians and patients; at its worst, it leads to wrong treatment choices. The instinctive discomfort that says "this claim is not right" is a healthy expression of professional ethics.

But professional ethics-as-justice and justice disease-as-fixation carry the same felt quality while performing entirely different functions. The first keeps the question "what is right for patients and society?" at its center. The second replaces that with "is my judgment right?". The weight of the question shifts, quietly.

Social psychologist Jonathan Haidt, in his research on moral emotions, observed that moral outrage serves both social and personal functions simultaneously. As a social force, it enforces norms. As a personal experience, it is also tied to the enhancement of one's own status and reputation. When outrage is internally registered as a "good feeling," the frequency with which one experiences it tends to increase. The same mechanism operates in pharmaceutical review.

How the Mind Learns 'Justice' ── Moral Licensing

Psychologists Benoît Monin and Dale Miller systematized the concept of moral licensing in a 2001 paper. After performing a virtuous act, people tend to grant themselves a license in the next decision — having done something good, they become more likely to act in self-serving ways in the following choice. It is a counterintuitive pattern, but it has since been replicated across many domains.

Translated into pharmaceutical review: a reviewer who stopped a problematic claim yesterday and felt the satisfaction of "having made the right call" approaches today's material with a self-image grounded in that experience. That foundation can stabilize judgment. But it can also reinforce the assumption that one's judgment is correct — making it harder to receive evidence to the contrary. This is where moral licensing meets self-serving bias.

Participants who established their moral credentials were subsequently more willing to express attitudes that could appear prejudiced. Monin and Miller found that a moral self-concept, once in place, tends to reduce the pressure for ongoing vigilance. ── Monin, B. & Miller, D.T., Journal of Personality and Social Psychology, 2001

After that first thank-you, the reviewer's mind learned one thing: pursuing rightness brings reward. This is adaptive learning. But when the reward circuit links "pursuing rightness" to "receiving reward," the answer to "why pursue rightness?" slowly changes. Protecting patients becomes entangled with, and eventually subordinated to, protecting the identity of being a rigorous reviewer.

The First Seed of Binary Thinking

Cognitive therapy founder Aaron T. Beck described dichotomous thinking as a core cognitive distortion: perceiving experience in terms of mutually exclusive categories, with no middle ground. David Burns, in his clinical applications of Beck's work, called it "all-or-nothing thinking." The research context was psychiatric; the cognitive structure applies equally to professional judgment.

Most pharmaceutical materials review involves genuinely gray judgment. The honest answer to "is this claim problematic?" is often: depends on context, depends on how the comparison standard is read, depends on the channel and audience. But a reviewer whose reward circuit has been trained on the pleasure of rightness will tend to resolve gray into binary. Not from laziness — from the opposite: because a clear verdict produces the felt sense of completed work that a held ambiguity does not.

This tendency begins as something that looks like professional rigor: "When in doubt, flag it." Over time, if gray-avoidance accumulates, the gray itself begins to read as moral weakness — as evasion, as "letting things through." This shift marks the first stage of justice disease.

Three Early Symptoms

In the early phase, these three symptoms are indistinguishable from "high standards" and "professional rigor." This is the central difficulty. The early symptoms of justice disease are fully expressible in the language of virtue. "I don't compromise." "Loose review fails patients." "The rules exist for a reason." All true statements. Which is precisely why the disease progresses unseen.

A Healthy Sense of Justice vs. Justice Disease ── An Invisible Boundary

Where does healthy professional ethics end and justice disease begin? The surface behavior cannot tell us — both produce the same action: flagging a problematic claim. The difference lies in the motivation driving the judgment and the width of the field of view.

The same external behavior, two internal architectures. The divergence is invisible from outside — and largely invisible from inside. The reason it remains invisible to the reviewer is that metacognition, the capacity to observe one's own thinking, is the first faculty that justice disease impairs. We return to this in episode six.

Why Call It a Disease?

The word "disease" is not rhetorical. It is not a clinical diagnosis. It is chosen to describe a specific structure: a system whose functional mechanism begins to corrode the purpose it was built to serve.

Systems thinker Russell Ackoff argued throughout his career that optimizing the parts of a system independently always degrades overall system performance. A reviewer who maximizes local correctness, blocking every borderline claim and resolving every ambiguity toward restriction, is locally optimal. But in the larger system of pharmaceutical communication, where physicians need accurate information to make treatment decisions and patients need clear explanations to participate in their own care, excessive restriction has its own harm: attenuation of legitimate information, defensive language that obscures rather than informs, and the chilling effect that makes companies overcautious about saying things that should be said.

The second reason for the word "disease" is that it progresses when left unattended. Episodes two through seven trace a worsening arc: field of view narrows to rules alone; binary thinking becomes habitual; collaborative relationships fracture; the reviewer's own professional function declines. A condition that began in genuine concern for patients ends by undermining the reviewer's ability to serve them well. The disease consumes the purpose it started from. That paradox is what earns it the name.

At this point in the story, the reviewer is not sick. They felt genuine satisfaction from legitimate work. But the reward has been registered. It will quietly color the next judgment, and the one after that. The entrance to justice disease opens in the moment of honest achievement.

The thank-you the reviewer received was earned. They caught a genuine error. They held a position under pressure. The satisfaction they felt had a legitimate basis. Any account of justice disease that dismisses this starting point distorts the truth. The disease does not begin in bad faith. It begins in good faith — and that is precisely what makes it difficult to see. The conversion of professional ethics into personal fixation happens inside legitimate experience, not in contrast to it. The reward circuit does not know the difference between "I protected a patient" and "I was right." Over time, with repetition, neither does the reviewer.

Over ten episodes, this series will trace the arc of that progression and the conditions under which awareness becomes possible. The next episode examines the first structural narrowing: the proximate trap — what happens when only the rule is visible and the context it exists to serve has left the frame entirely. The reviewer does not notice this has begun. The disease does not announce itself. It simply makes the world a little more legible, a little more binary, a little more satisfying to judge.